SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Crypto is trending as its dedicated community fervently champions the "OG meme" narrative of Rage Comics, positioning it as a "foundational meme reset" for the current market cycle. This active base expresses strong conviction, building an ecosystem with platforms like RageMaker and RageGames, and urging enthusiasts to "Return to the Memes" and "Rage On" to reclaim leadership in the meme coin space.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is drawing intense attention amid a controversial $200 million equity investment in Mr. Beast's company and a critical shareholder vote on authorizing 50 billion new shares. The community is fiercely divided, questioning if these strategic shifts represent a visionary pivot or a significant departure from its core Ethereum treasury focus, fueling concerns about dilution and management's priorities.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is currently trending as its CEO delivered a bullish presentation at a major healthcare conference, underscoring robust Miplyffa patient enrollment and an anticipated patent extension. This positive outlook, combined with a recent CFO departure and the appointment of a new board member with M&A experience, is fueling strong community speculation about a potential acquisition, even amidst discussions around a recent legal judgment against the company.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings Ltd (SPHL) is experiencing a parabolic surge, driven by news of its strategic partnership with Jiangsu GSO New Energy to develop solar-ready homes and green microgrids in Singapore. This, combined with its ultra-low float, has fueled intense community discussion around massive gains and short-squeeze potential, drawing comparisons to other highly volatile microcap runners.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is generating significant buzz due to a rumored major collaboration with POL and a recent integration with ACH, which the community views as a meaningful expansion of its utility. Many investors are anticipating that this "OG privacy coin" will follow the strong upward movement seen in Zcash amidst a broader resurgence of interest in the privacy token sector. Traders are actively discussing its potential to break key resistance levels and capitalize on its scarce supply for substantial upside.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science (MLEC) is trending following its recent 1-for-15 reverse stock split, which has drastically reduced its publicly traded float and ignited widespread community speculation about a potential short squeeze. Traders are actively drawing comparisons to other low-float stocks that have recently seen significant runs, anticipating high volatility driven by the tightened share structure and ongoing discussions around Nasdaq compliance. The stock's dramatic price action and the potential for a squeeze are key talking points among investors.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is attracting significant attention for its advanced GaN and SiC power solutions, which are crucial for high-efficiency architectures in next-generation AI data centers, including NVIDIA's 800-volt ecosystem. The community is highly engaged, anticipating potential contract announcements and a significant short squeeze, fueled by substantial short interest, as the company repositions for AI-driven growth.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is highly discussed following significant capital raises, including a $3 billion convertible preferred equity placement led by Apollo and a common stock offering, which are seen as pivotal for future acquisitions. The community is buzzing about CEO Brad Jacobs' proven 'playbook' for aggressive M&A in the building products distribution sector, with many viewing these moves as strategic funding for multiple large deals despite some short-term dilution concerns.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as the market grapples with the Senate's indefinite delay of key crypto legislation. Community discussion centers on whether this regulatory setback truly justifies the stock's sharp decline, with many perceiving it as market manipulation given Robinhood's expanding prediction market offerings and other growth initiatives. Investors are now closely watching crucial support levels for potential buying opportunities, amidst frustration over the stock's performance.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's is trending following a significant Q2 earnings beat and raised full-year guidance, signaling that its "Bold New Chapter" turnaround strategy is showing promising comparable sales growth, especially within its luxury segments. Community discussions are active, debating the sustainability of this retail revival, the stock's undervalued real estate assets in light of potential buyout interest, and the implications of management's cautious holiday spending outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) has been assigned a consensus rating of "Hold" from the five ratings firms that are currently covering the company, Marketbeat reports. One...

Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Grows By 27.1%

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling...

Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC

Acorn Capital Advisors LLC lowered its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 97.9% in the second quarter, according to the company in its most recent filing with...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have been given an average rating of "Hold" by the five ratings firms that are presently covering the stock, Marketbeat.com reports...

X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Zacks Research

Zacks Research lowered shares of X4 Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday...

Wall Street Zen Upgrades X4 Pharmaceuticals (NASDAQ:XFOR) to "Hold"

Wall Street Zen raised shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...

MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +12.66% and -7.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The firm is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

X4 Pharmaceuticals Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$3.62
Prev Close	$3.77
Open	$3.77
Dividend Yield	0.00%
50-Day Moving Average	$3.79
Beta	1.52
Avg. Volume	895,947.77
PE Ratio	-0.36

52-Week High	$24.43
52-Week Low	$1.35
Market Capitalization	$329.64M
EPS (Annual)	-$5.59
Price to Book	1.48
Revenue Per Employee	$17,881.12
Enterprise Value/EBITDA	N/A

XFOR
X4 Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XFOR News

XFORX4 Pharmaceuticals Inc